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a b s t r a c t
Tumor growth and metastases are dependent on interactions between cancer cells and the local
environment. Expression of the cell–cell adhesion molecule N-cadherin (Ncad) is associated with highly
aggressive cancers, and its expression by osteogenic cells has been proposed to provide a molecular
‘‘dock” for disseminated tumor cells to establish in pre-metastatic niches within the bone. To test this
biologic model, we conditionally deleted the Ncad gene (Cdh2) in osteolineage cells using Osx-cre
(cKO). Contrary to expectations, the metastatic breast cancer cell line PyMT-BO1 was able to form tumors
in bone and to induce osteolysis in cKO as well as in control mice. Despite absence of Ncad, bone marrow
stromal cells isolated from cKO mice were able to engage in direct cell–cell interactions with tumor cells
expressing either N- or E-cadherin. However, subcutaneous PyMT-BO1 and B16F10 tumors grew larger in
cKO relative to control littermates. Cell tracking experiments using the Ai9 reporter revealed the presence
of Osx+ and Ncad+ cells in the stroma of extra-skeletal tumors and in a small population of lung cells.
Gene expression analysis by RNAseq of Osx+ cells isolated from extra-skeletal tumors revealed
alterations of pro-tumorigenic signaling pathways in cKO cells relative to control Osx+ cells. Thus,
Ncad in Osx+ cells is not necessary for the establishment of bone metastases, but in extra-skeletal tumors
it regulates pro-tumorigenic support by the microenvironment.
 2021 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Metastases are responsible for 90% of cancer-related deaths, but
each of the steps leading to their development entails a combination
of events, both for ‘‘seed” cells to arise and reach the metastatic site
and for ‘‘soil” environments to become receptive to tumor engraft-
ment and growth of metastatic foci. Select tumor cells need to leave
their site of origin, circulate, evade immune surveillance, adhere to a
new ‘‘niche”, and modify a new environment so as to allow their
growth [1]. Cell-adhesion molecules have long been known to play
a key role in tumor progression and metastases, as they represent
a molecular mechanism for cells to orient in their surroundings
and communicate with neighboring cells [2].
Among cell–cell adhesion molecules, cadherins are
calcium-dependent trans-membrane glycoproteins that organize
into adherens junctions, which provide cell–cell anchorage via
linkage to the cytoskeleton [3]. Our group and others have shown
that N-cadherin (Ncad) is the main cadherin expressed in bone
cells, and that disruption of cadherin function or loss of the Ncad
gene (Cdh2) in osteolineage cells leads to delayed skeletal growth,
low bone mass and reduced osteoprogenitor number [4–6]. While
Ncad is important for mesenchymal cell fate determination [6], our
previous work has also shown that Ncad is dispensable for osteo-
blast support of the hematopoietic stem cell niche [7,8]. Aside from
cell-cell adhesion, cadherins also modulate cell migration and
specific signaling pathways. In particular, Cdh2 deletion or haploin-
sufficiency negatively affects MAPK/p38 [9,10], ERK, PI3K/Akt [11]
PTHR1 [12], and Wnt [5,13] pathways, whereas Ncad augments
FGFR signaling [14,15]. Many of these signaling systems are
involved in tumor growth.
During tumor development, some carcinoma cells undergo a
‘‘cadherin switch” from E-cadherin (Ecad) to Ncad, a hallmark of
epithelial-to-mesenchymal transition [16,17]. There is ample
in vitro and pre-clinical evidence suggesting that Ncad can favor
tumor progression. Overexpression of Ncad in tumor cells
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increases tumor cell migration and metastasis [18], while antibody
neutralization of Ncad hinders migration of cancer cell lines
in vitro and reduces metastases in xenograft models [19]. Further,
N-cad inhibitors reduce the growth of Ncad overexpressing pan-
creatic tumors [20] and improve response to chemotherapy in pre-
clinical models [21]. However, other preclinical studies show that
Ncad functions as a growth suppressor in K-ras-induced murine
pancreatic tumors [22], and interfering with Ncad may even stim-
ulate tumor growth in some mouse models of melanoma [23].
More to the point, published clinical trials using Ncad antagonists
for potential anti-tumorigenic action have been quite inconsistent
[24,25], highlighting the need of a better understanding of the role
of Ncad in tumorigenesis and cancer progression.
So far, research in this area has focused on Ncad in cancer cells,
and less attention has been given to how cadherins in resident cells
within the microenvironment contribute to the interaction
between the tumor and the tissue in which it grows. Recent work
has proposed that homo- or heterotypic interactions between Ncad
or Ecad on cancer cells and Ncad on osteogenic cells mediate the
engraftment of cancer cells in the bone marrow and eventually
lead to the development of bone metastases, via interference with
mTOR signaling [26]. Although these data support a pro-
tumorigenic action of Ncad in bone metastasis, whether removal
of Ncad from bone cells prevents bone metastasis, as predicted
by this biologic model, or whether adhesion between bone and
tumor cells is altered in the absence of Ncad, have not been tested
experimentally.
In this work, we have used mice with conditional Cdh2 ablation
in osteolineage cells driven by the Osterix (Osx) promoter, which
we have previously characterized [5,12], to ask whether lack of
Ncad in osteogenic cells protects these mice from bone engraft-
ment of cancer cells. Contrary to such expectations [26], we find
that tumor cells, similarly to hematopoietic stem cells, do not
require Ncad to engage in cell–cell adhesion with osteolineage
cells. We also find that subcutaneous tumors contain a
Ncad+ Osx+ stromal sub-population, which, upon loss of Ncad,
causes tumors to grow faster and lung metastases to develop ear-
lier. Our studies unveil an unexpected tumor-suppressive effect of
Ncad in stromal cells of the tumor microenvironment.
2. Material and methods
2.1. Animal models
All animal studies were designed and performed according to
the Animal Research Reporting of In Vivo Experiment (ARRIVE)
guidelines [27]; animal protocols and procedures were approved
by the Institutional Animal Care and Use Committee at Washing-
ton University in St. Louis (protocols 20140142 and 20170095).
We used mouse models that we have previously described and
characterized [5,7,12]. To mark osteolineage cells in vivo, we used
either B6.Cg-Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/J (Jackson laborato-
ries) mice, which carry a tetracycline-responsive Osx promoter
(Osx-Cre), or B6.Cg-Gt(ROSA)26Sor Tm9(CAG-tdTomato)Hze/J
(Ai9) (Jackson Laboratories) mice, and mated then with Cdh2Flx/Flx,
to generate Cdh2Flx/Flx::Osx-Cre mice (cKO), Ai9;Cdh2Flx/Flx::Osx-Cre
(Ai9-cKO) or Ai9:Osx-Cre. Unless otherwise indicated, all mice
were 6–12-week-old at the time of cancer cell inoculation. Mice
were housed in cages containing 2–5 animals each, in a room
maintained at constant 25 C on a 12-hour light/dark cycle, and
fed an ad libitum regular chow (PicoLab Rodent Diet 20, 5053;
TestDiet/LabDiet, St. Louis, MO), unless otherwise specified. We
have shown that Osx-driven Cdh2 cKO mice have stunted growth
and low bone mass [5]. To exclude any confounding effect on
tumor growth, in some experiments we delayed Osx-Cre activation
and Cdh2 ablation by suppressing the Tet-senstive Osx-Cre trans-
gene with doxycycline (Doxy) until 4 weeks of age [5,28]. In such
experiments, chow containing 200 ppm Doxy (Modified LabDiet
5058, 5BFB) was administered to dams and litters until weaning
(age 24–28 days). Mice were euthanized by ketamine/xylazine (av-
erage of 150/15 mg/kg body weight) cocktail intraperitoneal over-
dose and terminal intracardiac bleeding as approved by Animal
Studies Committee.
2.2. Cell lines and cultures
The B16-F10-Luc (B16) murine melanoma cell line (ATCC) is
derived from B16-F10 cells modified to express firefly luciferase
[29]. The 4T1-GFP-Luc (4T1) murine mammary tumor cell line,
which stably expresses firefly luciferase (Luc) and green fluores-
cent protein (GFP) reporters, was generously provided by Dr. David
Piwinica-Worms (MD Anderson Cancer Center, Houston, TX) and
cultured as previously described [30]. The PyMT-BO1-GFP-Luc
(BO1) cell line was derived from a primary tumor in MMTV-
PyMT mice, and modified to stably express GFP and firefly Luc
reporters [31]. The PyMT-B6 (B6) murine mammary tumor cell
line, also derived from a MMTV-PyMT tumor, was kindly provided
by Dr. David DeNardo (Washington University), and carries a click
beetle red luciferase-mCherry reporter [32]. Bone marrow stromal
cells (BMSC) were isolated from Cdh2flx/flx or Cdh2-cKO littermates
by flushing of the bone marrow by centrifugation, and filtering
over 70 mm cell strainers (VWR, Radnor, PA). They were cultured
in ascorbic acid-free aMEM (Gibco) supplemented with 40 mM
L-glutamine, 100 U/ml penicillin-G, 2.5 lg/mL amphotericin B,
100 mg/ml streptomycin, and 15% FBS. Cell cultures were kept at
37 C in a humidified atmosphere with 5% CO2; culture medium
was replaced every 3–5 days, according to established methods
[5,33]. Likewise, the mouse stromal cell line, ST2 [34], was cultured
and maintained in aMEM with antibiotics, as just noted.
2.3. Mouse tumor models
For intratibial injection, 5  104 PyMT-BO1-GFP-Luc cells in PBS
were injected in the left tibia under anesthesia with Ketamine/
Xylazine cocktail (100/10 mg/Kg BW) using a procedure previously
described [35], while PBS was injected in the right tibia. For mam-
mary fat pad (MFP) injection, 1  105 PyMT-B6 (B6) expressing
Luciferase and mCherry were mixed with matrigel (BD) and
injected into the mammary tissue of 8-week-old female mice. To
minimize differences between male and female subjects on tumor
growth experiments, 5  105 BO1 cells mixed with matrigel were
inoculated in the subcutaneous tissue of the flank of the mice. Gen-
der stratification of experimental groups is reported in Table 1 and
statistical analysis for gender effect on tumor growth showed no
differences for the subcutaneous inoculation. For subcutaneous
injections of melanoma cells, 1  106 B16 cells suspended in
100 mL PBS were injected into the flank, and tumor growth was
measured at each indicated time point by caliper. Tumor size
(mm3) was calculated by measuring the longest (L) and shortest
(S) diameters of tumor tissue using the formula: 0.5*L*S2.
2.4. Bioluminescence imaging
For live bioluminescence imaging (BLI), mice were shaved,
injected intraperitoneally with 150 mg/g D-luciferin (Biosynth,
Naperville, IL) in PBS, anesthetized with isoflurane 2.5%, and
imaged with a charge-coupled device camera-based biolumines-
cence imaging system (IVIS 100; Caliper, Hopkinton, MA; exposure
time 1–300 s, binning 8, field of view 12, f/stop 1, open filter, ante-
rior side), following described procedures [36]. Signal was dis-
played as photons/sec, and regions of interest were defined
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manually around the legs using Living Image and IgorPro Software
by an examiner blinded to mice genotype (Version 2.50).
2.5. Ex-vivo radiography
For assessment of osteolytic lesions, legs were dissected by
removing all skin and muscle tissues (but no extra-osseous tumor
outgrowth), fixed in formalin 10% for 48 h and preserved in 70%
ethanol until analysis. Digital contact radiographs were then taken
using a Faxitron UltraFocus100 scanner (Faxitron Bioptics, Tucson,
AZ, USA) and regions affected by osteolysis were measured using
ImageJ software (National Institutes of Health, USA), as described
[36], by an examiner blinded to genotype.
2.6. Flow cytometry of tissue homogenates
To determine the presence of tumor cells in the circulation,
blood samples were obtained by cardiac puncture and collected
in EDTA-coated microtitainers (BD). Mice were then perfused with
PBS through left and right ventricle infusion and bones, lungs, and
tumor tissues were resected. Bone marrow samples were obtained
by centrifugation and resuspended in PBS 1% FBS. To obtain cell
suspensions, tumors and lungs were minced and digested in
2 mg/ml collagenase A (Roche, Indianapolis, IN, USA) and DNAse
in DMEM (MilliporeSigma, St. Louis, MO, USA) for 30 min at
37 C. Digestions were quenched by washing with excess culture
media (20% FBS) and cells filtered through 70 lm cell strainers
(VWR). Red cell lysis was performed by incubating 10 min with
red blood cell lysis solution (MilliporeSigma) and washed with
excess PBS 1% FBS. For Ncad staining, samples were blocked with
rat anti-mouse CD16/32 (Cat. 93, Biolegend, San Diego, CA, USA)
for 10 min at room temperature, resuspended in 100 lL buffer with
primary anti-Ncad antibody (Cat. 806–820, MilliporeSigma) and
incubated on ice for 30 min, washed and incubated with APC-
conjugated rabbit-anti-mouse on ice for 30 min. Propidium Iodide
(20lg/sample) (MilliporeSigma) was used to stain for viability.
Flow cytometry was performed with a BD FACSCaliburTM (BD) flow
cytometer and analyzed by FlowJo (TreeStar/FlowJo LLC, Ashland,
OR, USA).
2.7. Cell-Cell adhesion
To test gap junction intercellular communication (GJIC), we
used a modification of a previously described method [37]. Tumor
cells were trypsinized (0.25% Trypsin-EDTA, MilliporeSigma),
resuspended in culture media, and loaded by 30-minute incuba-
tion in calcein-AM (Life Technology, Green Island, NY), when used
as ‘‘donor” cells, or labeled with the membrane permanent dye, DiI
(CellTrackerTM CM-DiI, Thermo-Fisher Scientific, St. Louis, MO),
when used as ‘‘acceptor” cells. Using the same procedures, BMSC
were loaded with calcein-AM, and ST2 cells with DiI. To assess
GJIC, DiI-labeled acceptor cells were ‘‘parachuted” onto a mono-
layer of calcein-loaded donor cells. After 2-h incubation to allow
cell–cell adhesion and gap junction formation, the percentage of
acceptor cells that had taken calcein from donor cells was deter-
mined by FACS as index of GJIC. As a negative control, sets of donor
and acceptor cells were placed on either side of a transwell system
(Corning, Lowell, MA), where they shared the culture medium but
were physically separated by a 0.4 lm transwell. Optical micro-
scopy images of tumor cells parachuted onto BMSC were obtained
on an Axiovert S100 fluorescence microscope (Zeiss, Jena, Ger-
many) at 40X magnification. Phase contrast and green and red flu-
orescence were then merged in ImageJ software (National
Institutes of Health, USA). After 8 h incubation, cells were trypsi-
nized, centrifuged and resuspended in FACS buffer for flow cytom-
etry for quantification of red and green fluorescence. Data were
acquired with a FACSCaliburTM (Becton, Dickinson and Company,
Franklin Lakes, NJ, USA) flow cytometer, and analyzed by FlowJo
10.0.7 software (TreeStar/FlowJo LLC, Ashland, OR, USA). The per-
centage of doubly fluorescent cells (acceptor cells that have taken
calcein) relative to the total red (acceptor) cells, was used as an
index of GJIC.
To test adhesion-dependent resistance to the chemotherapeutic
agent eirubulin [38], 4T1 cells were co-cultured with ST2 cells,
exposed to 200 nM eribulin for 24 h, and released from the tissue
culture dish by trypsin-EDTA for 5 min. As tumor cells detach more
easily from plates and from each other than stromal cells, this pro-
cedure enriches the cell suspension for tumor cells, while stromal
cells remain attached to the plate. Suspended cells were washed in
cold PBS and prepared for cell cycle analysis as per Abcam protocol
(https://www.abcam.com/protocols/flow-cytometric-analysis-of-
cell-cycle-with-propidium-iodide-dna-staining). Briefly, cells were
dehydrated in 70% ethanol for a minimum of 5 h at 4 C, washed in
ice-cold PBS, incubated with 5 mg RNAse A for 1 h at 37 C, and
stained with 20 ng Propidium Iodide (MilliporeSigma, St Louis,
MO). After washing in PBS, pellets were resuspended in FACS buffer
(PBS 2% FBS) and cells subjected to flow cytometry (BD FACSCal-
iburTM, BD, Franklin Lake, NJ). FlowJo was used to identify peaks
for G1, S, and G2 phases.
2.8. RNAseq analysis
To prepare cells for RNAseq analysis, subcutaneous tumors orig-
inating from injection of MMTV-BO1 cells in Cdh2-cKO;Ai9 and
Osx-cre;Ai9 mice were excised and incubated with collagenase.
Cells in suspension were stained for CD45 and sorted with a FACS
Aria (BD) to exclude GFP + cells (tumor cells) and separate single
positive CD45+, single positive Osx+ (tdTomato fluorescence) cells,
and GFP- CD45–;Osx– triple-negative cells. To obtain adequate
numbers of cells for transcriptomic analysis, we inoculated 6
Cdh2-cKO;Ai9 and 4 Osx-cre;Ai9 mice and selected, from these cell
preparations, those samples that met the quality control test for
RNA integrity (average RIN = 8.95). Based on this protocol, we sub-
mitted 2–3 biological replicates per group of cells, per each geno-
type to RNAseq analysis. Samples were prepared with the
Clonetech SMARTer version 1 kit according to manufacturer’s pro-
tocol, indexed, pooled, and sequenced across two 50 base-pair
single-end Illumina HiSeq 3000 lanes on a single flowcell. Basecalls
and demultiplexing were performed with Illumina’s bcl2fastq soft-
ware with a maximum of one mismatch in the indexing read. RNA-
seq reads were then aligned to the Mus musculus Ensembl release
76 top-level assembly with STAR version 2.0.4b. Gene counts were
derived from the number of uniquely aligned unambiguous reads
by Subread:featureCount version 1.4.5. Sequencing performance
was assessed for the total number of aligned reads, total number
of uniquely aligned reads, and features detected. The ribosomal
fraction, known junction saturation, and read distribution over
known gene models were quantified with RSeQC version 2.3.
All gene counts were then imported into the R/Bioconductor
package EdgeR and TMM normalization size factors were calcu-
lated to adjust for samples for differences in library size. Ribosomal
genes and genes not expressed in at least two samples greater than
one count-per-million were excluded from further analysis. The
TMM size factors and the matrix of counts were then imported into
the R/Bioconductor package Limma. Performance of the samples
was assessed with principle components analysis. Weighted likeli-
hoods based on the observed mean–variance relationship of every
gene and sample were then calculated for all samples with the
voomWithQualityWeights. Differential expression analysis was
then performed to analyze for differences between the cKO
Osx + CD45 negative cells and wild-type Osx + CD45 negative cells
as well as the cKO double negative and wild-type double negative
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cells. The results were filtered for only those genes with p-values
less than or equal to 0.05 and log2 fold -changes greater than an
absolute value of 2.
For each contrast extracted with Limma, global perturbations in
known Gene Ontology (GO) terms, MSigDb terms, and KEGG path-
ways were detected using the R/Bioconductor package GAGE to
test for changes in expression of the reported log2 fold-changes
reported by Limma in each term versus the background log2
fold-changes of all genes found outside the respective term. The
R/Bioconductor package heatmap3 and Pathview were used to dis-
play heatmaps or annotated KEGG graphs across groups of samples
for each GO term or KEGG pathway (respectively) with a
Benjamini-Hochberg false-discovery rate adjusted p-value less
than or equal to 0.05.
2.9. Statistical analysis
Statistical analyses were performed using Prism version 8
(GraphPad Software, Inc., La Jolla, CA, USA). Two-group compar-
isons were performed by Student’s t-test. Multiple-group means
were analyzed by one-away analysis of variance (ANOVA) followed
by post hoc analysis for multiple group comparisons. Two-way
ANOVA was used to analyze the contribution of multiple indepen-
dent variables, and for repeated measures datasets. After ANOVA,
Bonferroni or Sidak post-hoc test was used for comparison of indi-
vidual data points. Mann-Whitney test was used for non-normally
distributed data. Categorical data sets were compared using Fish-
er’s exact test. Unless otherwise specified, data are expressed as
median and interquartile range.
2.10. Data statement
Sequencing data are deposited in GEO under accession code
GSE143586 https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc
= GSE143586. All other research data are available upon request.
3. Results
3.1. Loss of Ncad in osteogenic cells does not affect cancer growth in
bone, but favors tumor growth at extra-skeletal sites
As noted, Ncad in osteolineage cells has been proposed to medi-
ate heterotypic interactions with Ecad in cancer cells and allow
tumor cell homing to bone [26]. To test this biologic model, we
inoculated BO1 cells, which have high propensity to metastasize
to bone, into one tibia of cKO or Cdh2flx/flx littermates (henceforth
noted as wild type-equivalent: WTe); PBS was injected in the con-
tralateral tibia as control. To control for tumor growth at other
sites, we also inoculated the B6 parental breast cancer cells (B6)
into the mammary fat pad (MFP) of control and mutant mice. We
first verified that while BO1 cells express Cdh2 mRNA, B6 cells
express Ecad more abundantly than Ncad (Sup. Fig. 1A, B). We
noted no differences in tumor growth in tibiae of cKO mice relative
to WTe by BLI followed for 2 weeks after tumor cell inoculation at
8 weeks of age (Fig. 1A left hindlimb circles, B). Closely similar
results were obtained upon injection of BO1 cells in tibiae of Doxy
treated mice, in which OsxCre is activated post-natally [28], with
equal intratibial growth of BO1 tumors (Sup. Fig. 1C). On plain
radiographs extensive bone destruction occurred equally in both
genotypes in the inoculated tibia and in the adjacent femur
(Fig. 1C), and there were no differences in tumor outgrowth
through the cortex into the adjacent soft tissue area (Sup.
Fig. 1D, E); whereas the contralateral, PBS-injected hind limbs,
showed no overt signs of osteolysis (not shown). Surprisingly, BLI
revealed not only larger orthotopic MFP tumors in cKO mice
(Fig. 1A, squares) but also the presence of soft tissue activity in
the chest of cKO mice, rapidly increasing with time (Fig. 1D). On
necropsy, we found a larger number of lung metastases in cKO
mice than in WTe control mice (Fig. 1E). Indeed, 70% of cKO devel-
oped metastases by day 10, vs. 40% of controls (5/7 vs 2/5)
(p < 0.05, Fisher’s test).
Fig. 1. Tumor growth in bone and extraskeletal tissues. Wild type equivalent (WTe) and cKOmice were inoculated with GFP-Luciferase-labeled BO1 cells in the left tibiae, and
mCherry-Luciferase-labeled PyMT-B6 in the MFP. (A) Representative experiment showing engraftment in the tibia (right oval) and MFP (rectangle) in both mice by BLI. (B)
Quantitation of BLI intensity at days 7 and 13 after tumor inoculation. (C) Plane radiographs of hindlimbs of WTe and cKO (treated with doxycycline during breeding)
littermates 3 weeks after BO1 inoculation into the tibia showing extensive bone destruction. (D) Soft tissue chest BLI activity at day 10 and 18 after in WTe and cKO mice. (E)
Presence of large and numerous metastatic nodules in the lungs of cKO relative to WTe mice inoculated with BO1 and B6 cells. Tumor growth, measured by caliper, over time
after subcutaneous inoculation of either (F) B01 cells, or (G) B16 melanoma inWTe or cKO littermates (median and interquartile range; n = 3–6 per group). P-values reflect the
genotype effect in a two-way ANOVA (for BO-1: genotype F = 10.43, p = 0.027; time F = 11.39, p < 0.001; interaction F = 1.85, p = 0.128. For B16-F10: genotype F = 4.60,
p = 0.045; time F = 20.63, p < 0.001; interaction F = 0.94, p = 0.407). *p = 0.0015 vs. WTe, after Sidak’s adjustment for multiple comparisons.
F. Fontana, J. Xiang, X. Su et al. Journal of Bone Oncology 28 (2021) 100356
4
Therefore, we asked whether loss of Ncad in Osx+ cells might
affect the growth of tumors outside the bone. To this end, we inoc-
ulated BO1 cells in the subcutaneous tissue of cKO and control lit-
termates and followed tumor growth by caliper measurements.
Tumor volume grew significantly larger with time in cKO mice
compared to WTe littermates (Fig. 1F). The same result was consis-
tently obtained in 4 independent experiments, regardless of doxy-
cycline administration, with an overall increase of 30% in cKO vs
WTe after 10–15 days post-inoculation (Table 1). Likewise, a signif-
icantly larger increase in tumor growth in cKO relative to WTe
mice also occurred when the B16-F10 melanoma cell line was
injected subcutaneously (Fig. 1G). Suggesting a possible increased
lethality, 2/5 cKO mice died before two weeks after inoculation,
while none died in the WTe group (p = 0.07; Fisher’s test). There-
fore, Ncad expression in osteogenic (Osx+) cells is not required
for tumor growth in the bone and for tumor associated bone loss;
however, loss of Ncad in osteogenic lineage, Osx+, cells alters the
tumor microenvironment outside the bone, favoring tumor
growth.
3.2. Loss of Ncad in osteogenic cells does not decrease dissemination of
tumor cells to bone
To evaluate whether ablation of Ncad in these Osx+ osteogenic
cells prevents bone metastasis, as it would be predicted if Ncad/
Ecad interactions were required for early stages of metastases
[26], we inoculated again the highly metastatic BO1 cells in the
flank subcutaneous tissue of WTe and cKO mice, and let tumors
grow until 2 cm of maximum diameter, before collection for flow
cytometry (Fig. 2A). There was no difference in the number of bone
marrow GFP+ cells – representing disseminated tumor cells (DTC)
– between tumor-bearing WTe and cKO littermates (Fig. 2B). Like-
wise, we found no difference in the number of Ncad-expressing
primary tumor cells (Sup. Fig. 2A); and cell viability within tumors
was also similar between genotypes (Sup. Fig. 2B), suggesting that
lack of Ncad in Osx+ cells does not prevent subcutaneous tumor
cells from reaching and/or being retained in the bone. We then
tested whether lack of Ncad in osteogenic cells may prevent tumor
cell dissemination or permanence in the bone marrow and metas-
tasis over the long-term. After subcutaneous inoculation of BO1
cells, we performed survival surgery (marginal resection) when
tumors reached 1 cm diameter; then followed the mice for devel-
opment of recurrence or metastases by BLI and survival until
175 days after inoculation (160–155 after surgery) (Fig. 2C). Tumor
weight was well matched between genotypes at resection, con-
firming a balanced tumor burden (not shown). No mice developed
local recurrence, but BLI showed signs of distant site metastases as
soon as day 25 in 33% (2/6) of cKO and 11% (1/9) of WTe mice
(Fig. 2D). Only one WTe mouse developed bone metastases; none
were observed in cKO, and most metastatic foci were found in
the lungs after 160–155 days from primary tumor resection. In
most cases, there was more severe metastatic disease in cKO litter-
mates, as exemplified in Sup. Fig. 2C. However, even though the
median relapse-free survival (defined as evidence of recurrence
by BLI or death) was reduced in cKO relative to WTe mice (41.5
vs. 89.0 days), the difference was not statistically significant
(Fig. 2E). To determine the presence of DTC in long-term survivors,
we collected peripheral blood and bone marrow in 3 WTe and 3
cKO littermates that were free from BLI-detectable metastases
175 days after tumor inoculation. We found no significant differ-
ence between genotypes in the number of peripheral blood or bone
marrow GFP + cells (Fig. 2F, G). Thus, loss of Ncad in Osx + cells
does not interfere with presence of DTC in the bone microenviron-
ment. In all, our data suggest that Ncad expression by osteogenic
cells does not affect DTC engraftment and retention in the bone.
3.3. Loss of N-cadherin in bone marrow stromal cells does not alter
adhesion to tumor cells
We then asked whether loss of Ncad disrupts adhesion between
osteogenic stromal cells and cancer cells in vitro. To this end, we
applied two approaches, 1) the ability of tumor and stromal cells
to form functional gap junctions, which requires cells to adhere
and anchor to each other, and 2) cell adhesion mediated-drug
resistance. To model heterotypic adhesion between tumor Ecad
and bone Ncad, we used bone marrow stromal cells (BMSC), which
are enriched in osteogenic cells expressing Ncad [5,7,12] and the
gap junction protein connexin43 (Cx43) [33]. As shown earlier,
breast cancer 4T1 cells express Ecad but not Ncad mRNA [39]
(Sup. Fig. 1A); they also express Cx43 (Sup. Fig. 3A). To test for IGJC,
DiI-labeled 4T1 tumor cells were parachuted on a monolayer of
calcein-loaded BMSC isolated from either WTe or cKO. As illus-
trated in Fig. 3A, after 1 h incubation, DiI-stained cells (quadrant
ii) that came in contact with calcein-loaded WTe BMSC (iii, blue
arrows) were also green (iv), demonstrating diffusion of calcein
from donor BMSC to acceptor tumor cells. Parachuting DiI-
labeled 4T1 tumor cells onto cKO calcein-loaded BMSC resulted
in similar uptake of green fluorescence by acceptor tumor cells
(Fig. 3B); thus indicating that lack of Ncad in osteogenic cells does
not alter their ability to engage in direct cell–cell interactions. In
fact, quantitation of cell coupling using FACS on cells released after
8-h co-incubation demonstrated that almost the entire population
of 4T1 tumor cells had taken calcein from donor BMSC, regardless
of their genotype (Fig. 3C). The need of cell–cell contact for calcein
diffusion was confirmed by lack of calcein uptake by 4T1 tumor
cells when seeded on the opposite side of a transwell system with
calcein-labeled WTe BMSC (Fig. 3C). Validation experiments also
demonstrated that calcein diffusion from tumor cells to BMSC
was mediated by Cx43, since Gja1 knock-down by shRNA in 4T1
cells (Sup. Fig. 3A) greatly reduced calcein transfer to acceptor cells
(Sup. Fig. 3B, C). We also tested the melanoma cell line B16-F10,
which expresses Ncad [40], in the GJIC assay. Calcein-labeled
B16-F10 cells were also able to pass the fluorescent dye to both
WTe and cKO BMSC, whereas when tumor and bone marrow cells
Table 1
Subcutaneaus tumor growth in N-cadherin deficient and wild type mice.
Expt. Number Genotype N Final Day Post-injection Tumor size at excision (mm3)a Pb
1c Cdh2fl/fl (Wte) 5F, 6 M 10 413.4e 0.041
Cdh2fl/fl;Osx-cre (cKO) 4 M 501.2 (291.5)
2c Cdh2fl/fl (Wte) 4F, 3 M 13 838.4 (327.5) 0.008
Cdh2fl/fl;Osx-cre (cKO) 3F, 2 M 1065.1 (271.1)
3d Ai9;Cdhfl/fl (Wte) 2F, 2 M 13 307.3 (66.8) 0.003
Ai9;Cdh2fl/fl;Osx-cre (cKO) 2F, 3 M 711 (355.2)
4d Cdh2fl/fl (Wte) 3F, 6 M 15 863.5 (299.1) 0.002
Cdh2fl/fl;Osx-cre (cKO) 2F, 4 M 1229.9 (434.8)
F females, M males; amean (SD); bfor genotype effect (two-way ANOVA on repeated measurements during the entire observation period). cDoxycycline treatment (during
pregnancy and until weaning), dno doxycycline treatment. en = 2.
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were separated in a transwell system, no calcein transfer occurred
(not shown). Thus, even though not all BMSC would be expected to
be targeted by Osx-Cre, these results show no evidence that abla-
tion of Cdh2 in Osx expressing cells (which are abundantly present
in BMSC cultures) alters the ability of these cells to directly com-
municate with tumor cells via gap junctions.
To test cell adhesion mediated-drug resistance, we co-cultured
4T1 breast cancer cells with BMSC isolated from either WTe or
Cdh2-cKO littermates, and treated them with eribulin, a micro-
tubule inhibitor used in breast cancer therapy [30]. As expected
for microtubule dysfunction, exposure of 4T1 to eribulin resulted
in a 4-fold increase in the number of cells in G2. By contrast, only
half as many 4T1 cells co-cultured with either WTe or cKO BMSC
were arrested in G2, suggesting that co-culture with the stroma
decreased sensitivity to chemotherapy, and that this effect is not
altered by lack of Ncad in ostegenic cells (Fig. 3D). In all, these
experiments show that Ncad deletion in stromal cells does not pre-
vent osteogenic cell adhesion and communication with tumor
cells.
3.4. Ncad is expressed in a subset of Osx + cells present in the tumor
microenvironment and at extra-skeletal sites
The larger subcutaneous tumor growth and the apparent
increased severity of metastatic disease in cKO mice prompted us
to ask whether Ncad deletion in extra-skeletal cells may be
involved in modulating tumorigenesis. Indeed, in a parallel study
using the Ai9:Osx-cre reporter mouse we found that a proportion
of cells in the stromal component of tumors generated by subcuta-
neous inoculation of breast (BO1) and melanoma (B16-10) cells
express red fluorescence (TdTOsx+) [41,42]. We confirmed the pres-
ence of TdTOsx+ cells in the stromal component (GFP– CD45– pop-
ulation) of orthotropic BO1 tumors grown in either WTe mice or in
Cdh2 cKO mice, with no significant differences between the two
genotypes (Fig. 4A). FACS analysis using an anti-Ncad antibody fur-
ther revealed that a sub-population (5–6%) of these tumor-
associated TdTOsx+ GFP– CD45– cells express Ncad (Fig. 4B).
Although in the adult skeleton Osx expression is generally thought
to be restricted to bone, emerging data suggest that Osx-Cre also
targets extra-skeletal tissues in adult mice [43–45]. Since the lungs
are frequent sites of breast cancer metastasis, we isolated lung
cells from non-tumor bearing mice by collagenase digestion and
identified TdTOsx+ cells by FACS (about 4% of the entire population;
Fig. 4Ci, ii). TdTOsx+ were also present, in smaller proportion, in the
subcutaneous tissue (Fig. 4Ciii, iv). In cultures of stromal cells iso-
lated from MFP of normal mice, TdTOsx+ cells exhibited a flattened,
irregular shape with multiple small processes, remindful of osteo-
blasts or fibroblasts (Fig. 4Di, ii); and in lung sections, TdT+ cells
were scattered in the lung interstitial tissue (Fig. 4Diii, iv). Flow
cytometry confirmed expression of Ncad in approximately 5% of
the TdTOsx+ population of MFP cells, and in a smaller proportion
of lung interstitial cells. In both tissues, Ncad+ cells were unde-
tectable among the TdTOsx+ population in cKO; Ai9 mice (Fig. 4E,
F). Thus, Ncad is expressed in subsets of Osx+ cells present in the
Fig. 2. Metastatic dissemination of extraskeletal tumors. (A) BO1 cells were inoculated into WTe and cKO and let grow until they reached 2 cm maximum diameter, when
tumors and bone marrowwere harvested for flow cytometry. (B) Percentage of GFP+ cells in the bone marrow of WTe and cKOmice. (C) Mice were inoculated subcutaneously
with BO1 cells; when tumors reached 1 cm of maximum diameter, they were surgical resected and mice were followed for recurrence, distress symptoms (dyspnea, severe
weight loss), survival and evidence of metastases by BLI. (D) Percent of mice without local recurrence but with metastasis (by BLI) at day 175 post-inoculation at three
different sites. (E) Kaplan-Meyer analysis of relapse-free survival following primary MFP tumor resection (subjects at risk: WTe = 9, cKO = 6; p = 0.476, Log-rank test). Percent
of GFP+ cells relative to total cells by flow cytometry of (F) peripheral blood, or (G) bone marrow of long-term survivors without evidence of tumor progression (negative for
recurrence in multiple BLI) at day 175 from inoculation. P-values shown in B, F, and G calculated using Mann-Whitney test.
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tumor microenvironment at extra-skeletal sites, but also in normal
lung and subcutanoues tissue.
3.5. Loss of N-cadherin induces protumorigenic gene expression
signatures in tumor microenvironment Osx+ cells
To explore how loss of Ncad may affect the transcriptome of
tumor microenvironment Osx+ cells, we applied RNAseq analysis
to cells isolated from subcutaneous BO1 tumors grown in Ai9;
Osx-cre or Ai9;cKO mice. After tumor excision, cell suspensions
were sorted after GFP (tumor cells) and CD45 (hematopoietic cells)
subtraction into TdTOsx+ and TdT– populations (Sup. Fig. 4), and
mRNA extracted for library preparation and high-throughput
sequencing. We obtained an average of 32 million reads for each
of the cDNA libraries, with an average of 72% reads uniquely
mapped to the mouse reference genome. After the gene counts
were filtered for ribosomal and low expressing genes, the counts
were Voom transformed with Limma. We applied an unbiased
method to evaluate the relationship among the four groups of cells
(WTe TdTOsx+, Wte TdT–, cKO TdTOsx+, cKO TdT–). Principal compo-
nents analysis revealed that nearly 90% of the total variance was
accounted for in the first principal component, indicating that
the cell sorting procedures were adequate, and that most of the
changes between conditions observed were biological rather than
technical in origin. Further scrutiny revealed that Wte TdT– cells
(representing tumor microenvironment stromal cells that are not
targeted by Osx-Cre) from Cdh2 deficient and control mice clus-
tered close to each other, while TdT + cells from tumors grown in
Ai9;cKOmice grouped separately with moderate cluster separation
between groups. The moderate cluster separation indicated that
the differentials at the gene level would be modest in both signif-
icance and magnitude and the post-hoc differential expression
analysis results with Limma would need to be adjusted accordingly
(Fig. 5A). We first analyzed the transcriptional profile of tumor
associated TdTOsx+ and TdTOsx– cells from WTe (Ai9) mice and
found > 2000 genes differentially regulated (Fig. 5B). Pathway anal-
ysis showed that TdTOsx+ upregulate genes involved in collagen
production and extracellular matrix processing, relative to TdTOsx–
(Fig. 5C). Univariate analysis revealed that TdTOsx+ express signifi-
cantly higher abundance of osteoblast genes than do TdTOsx– cells,
specifically RANKL (Tnfsf11), periostin (Postn), parathyroid hor-
mone receptor (Pthr1), the chondro-osteogenic specific metallo-
proteinases Mmp9 and Mmp13 and fibrillar collagens Col27a1,
Col24a1, and of course, Col1a1 and Col1a2 mRNA (Fig. 5C). Interest-
ingly, TdTOsx+ cells express significantly less alkaline phosphatase
(Alpl) mRNA. On the other hand, analysis of canonical cancer asso-
ciated fibroblast (CAF) markers revealed that TdTOsx+ express sig-
nificantly less FSP1 (S100a4) and Cav1 mRNA relative to TdTOsx–
cells, with the exception of Fsp, which was slightly increased. Other
markers shared by CAF and osteolineage cells, such as Igtb1, a-SMA
(Acta2) and Pdgfa/b were also marginally higher in TdTOsx+ relative
to TdT– cells (Fig. 5D).
Further analysis of differentially expressed genes between cKO
TdTOsx+ and WTe TdT+ cells revealed that using p  0.05 cut-off,
551 genes were up-regulated in cKO TdTOsx+ cells with log2 fold-
changes between 0.49 and 7.89, while 739 genes were down-
regulated with a log2 fold-change between 0.50 and 7.30.
Increasing the stringency to p  0.01 and an absolute value log2
fold-change  2, we found 33 up-regulated genes and 85 down-
regulated genes (Fig. 6A). To further elucidate the functional
Fig. 3. Intercellular gap junctional communication (IGJC) and cell contact dependent chemoresistance. DiI-labeled 4T1 cells were parachuted on a monolayer of calcein-
loaded BMSC isolated from (A) WTe or (B) cKO mice. Live optical imaging showing (i) phase contrast, (ii) DiI fluorescence, (iii) calcein fluorescence, and (iv) merged image.
Arrowheads indicate DiI-labeled cells that have taken calcein (in yellow in the merged image) as index of IGJC. Quantitation of IGJC as percentage of (C) DiI + Calcein + 4T1
breast cancer cells relative to all DiI cells assessed by flow cytometry. In the Transwell condition, cells were grown on opposite sides of a semi-permeable membrane to allow
fluid exchange but prevent cell–cell contact. (D) 4T1 cells cultured alone or in the presence of WTe or cKO BMSC, as indicated, were exposed to 200 nM eirubulin or vehicle for
24 h and processed for cell cycle assessment by flow cytometry. Data are presented as percentage of cells in G2 relative to the total number of cells. (For interpretation of the
references to colour in this figure legend, the reader is referred to the web version of this article.)
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impact of these differentially expressed genes, we performed a
GAGE log2 fold-change analysis of all tested genes against the
Molecular Signature Database (MSigDb). Among the 1,290 genes
identified as significantly differentially regulated between cKO
TdTOsx+ and WTe TdT + cells, we found 212 genes that contained
transcription factor binding motifs across 31 significantly enriched
MSigDb transcription factor motif target gene sets with Benjamini-
Hochberg adjusted p-values 0.05 (Sup. Fig. 5). Frequency analysis
of the 212 genes across the gene sets revealed that Nfat, Foxo4,
MAZ, Sp1, Lef1, Meis1, and Chx10 had the greatest number of recur-
Fig. 4. TdTOsx+ and Ncad+ cells among lung and subcutaneous cells. (A) Percentage of TdT+ cells of total GFP– CD45– cells in the stromal component of orthotropic BO1
tumors grown in either Ai9;Osx-cre or Ai9;cKO mice, assessed by flow cytometry. (B) Percentage of Ncad+ cells among TdTOsx+ GFP– CD45– cells in the stromal component of
orthotropic BO1 tumors grown in either Ai9;Osx-cre mice. (C) Flow cytometry analysis of TdT+ cells isolated from (i, ii) lungs and (iii, iv) subcutaneous tissue of Ai9 or Ai9;
Osx-cre mice. (D) Cultures of (i, ii) mammary fat pad stromal cells of Ai9;Osx-cre mice showing large, flattened cells with red fluorescence; and frozen sections of lungs of (iii)
Ai9 or (iv) Ai9;Osx-cre mice showing a few, scattered TdT+ cells in the lung interstitial tissue. Quantitation of flow cytometry data showing the proportion of Ncad+ cells in (E)
the mammary fat pad (MFP) and (F) lung tissue of Ai9; Osx-Cre and Ai9;cKO mice. (For interpretation of the references to colour in this figure legend, the reader is referred to
the web version of this article.)
Fig. 5. RNAseq analysis of tumor associated TdTOsx+ cells. Cells isolated from BO1 tumors grown in Ai9;Osx-cre or Ai9; Osx-cre mice were FAC-sorted for TdT+ and TdT– from
the GFP– CD45– population (to exclude tumor and hematopoietic cells) for RNAseq analysis. (A) 3-D plot representing principal component analysis, where each dot
represents cells from one tumor (one mouse). (B) Heat map and (C) pathway analysis of differentially expressed genes. (D) Univariate analysis of differential expression of
molecular markers for osteogenic cells (green), or CAF (orange), or shared markers (gray). (For interpretation of the references to colour in this figure legend, the reader is
referred to the web version of this article.)
F. Fontana, J. Xiang, X. Su et al. Journal of Bone Oncology 28 (2021) 100356
8
ring genes, with Lef1 being the most highly represented (Fig. 6B).
Univariate analysis also revealed that the tumor suppressor gene,
Pten was downregulated in cKO TdTOsx+ cells; while the pro-
tumorigenic protease Adam15, which is negatively regulated by
Pten [46], was up-regulated in cKO TdTOsx+ relative to WTe
TdT+ cells (Fig. 6C, D). By contrast, there was no significant differ-
ential expression of other cadherins or cell adhesion molecules in
cKO TdTOsx+ cells. Of note, Cdh11 was the most abundantly
expressed, consistent with a stromal, osteolineage nature of these
cells (Sup. Fig. 6A, B). Pathway analysis through KEGG pointed
towards activation of the Ras/ERK and PI3K pathways in
cKO TdTOsx+ cells (Sup. Fig. 7A, B).
4. Discussion
These studies demonstrate that loss of Ncad in osteogenic
(Osx-cre-targeted) cells does not alter tumor growth in bone or metas-
tasis to bone but results in an unexpected pro-tumorigenic effect in
extra-skeletal tumors. This effect is not related to tumor cells adhesive
properties, but rather to an anti-tumorigenic action of Ncad in
previously unrecognized Osx+ cells present in the stromal compartment
of extra-skeletal tumors; in the absence of Ncad, these cells acquire a
pro-tumorigenic transcriptional signature.
Ncad in osteogenic cells has been proposed as a mechanism for
the recruitment and retention of DTC in the bone marrow, via het-
erotypic interactions with Ecad on tumor cells [26]. Of note,
mechanically active heterotypic interactions between Ncad in
CAF and Ecad in tumor cells facilitate tumor cell migration and
tumor growth [47]. Yet, clinical studies using Ncad antagonists
have yielded discordant results [24,25]. Since adhesion of DTC to
the bone microenvironment can favor the permanence and
chemoresistance of cancer cells capable of initiating metastatic
relapse, even in the absence of immediate bone metastatic growth
[48], we leveraged a model of conditional Cdh2 deletion in the
osteogenic lineage [5,12], to investigate whether Ncad is indeed
the molecular anchor tethering cancerous cells to the bone. Con-
trary to expectations, we found that Ncad in osteogenic cells is
not necessary for the growth of tumor cells inoculated into the
bone, nor for tumor-induced osteolysis. Notably, loss of Ncad in
the osteogenic lineage did not prevent initial tumor cell dissemina-
tion (in the presence of a large tumor), long-term permanence of
disseminated cells after tumor resection, or late-recurring meta-
static growth. Therefore these data, obtained in a validated genetic
model of selective Cdh2 ablation in Osx+ cells [5,12], do not sup-
port a prominent role of Ncad in the establishment or development
of bone metastases. It should be noted that most cell types express
a variety of adhesion molecules, and such redundancy may well
explain why lack of Ncad does not alter the ability of BMSC, which
contain osteogenic cells, to engage in cell–cell adhesive interac-
tions with tumor cells expressing either Ecad or Ncad. Thus, the
anti-tumorigenic action on Ncad is most likely independent of
cell–cell adhesion.
The most striking, unexpected findings of this work are the lar-
ger growth of tumors and higher frequency of metastasis at extra-
skeletal sites in mice with Osx-cre-driven Cdh2 ablation. As noted,
while Osx expression is generally thought to be restricted to bone,
emerging data suggest that Osx is also present in extra-skeletal tis-
sues in adult mice [43–45]. Here, we demonstrate that Osx-cre tar-
gets small populations of stromal cells within the tumor
microenvironment outside of the bone, and in normal subcuta-
neous and lung tissue. While these observations do not exclude
that bone resident Osx-cre-targeted cells contribute to extra-
skeletal effects via endocrine mechanisms [49], or mobilization of
hematopoietic cells [50], it is likely that these tumor associated
TdTOsx+ cells participate in shaping the microenvironment of
extra-skeletal tumors. The relatively low frequency of TdTOsx+ cells
in healthy subcutaneous tissue (<1%) compared to nearly 15% in
subcutaneous tumor tissue suggests that either TdTOsx+ cells are
recruited to the tumor, or the tumor cues stromal cell expression
of Osx or expansion of the resident TdTOsx+ population. Cells with
osteogenic capacity are present in the circulation of animals and
humans [51], and recent data suggest that circulating osteocalcin
positive cells may represent an early marker of bone metastasis
[52]. In related work with other collaborators, we also find
Osx+ cells in peripheral blood, but these cells are hematopoietic
in origin [41,42], and ontogenetically unrelated to the tumor asso-
ciated TdTOsx+ cells described here, which were selected for not
expressing CD45. In fact, our transcriptomic analysis show that
relative to the TdTOsx– population, tumor associated TdTOsx+ cells
have a mesenchymal, osteogenic signature, as they up-regulate
genes involved in collagen matrix production and processing, as
well as osteoblast-specific markers. Of note, markers of CAF not
shared with osteoblasts are either down-regulated or modestly
Fig. 6. Transcriptional profile of Ncad+ and Ncad– TdTOsx+ cells. Cells isolated from BO1 tumors grown in Ai9;Osx-cre or Ai9; Osx-cremice were FAC-sorted for TdT+ and TdT–
cells after subtraction of GFP+ and CD45+ cells. (A) Volcano plot showing differentially up-regulated (red) and down-regulated (blue) genes in TdT+ cells from tumors grown in cKO
relative to those grown inWTe mice. (B) Heat map of transcription factor binding motifs significantly differentially up-regulated (red) or down-regulated (blue) in TdT+ cells from
tumors grown in cKO relative to those grown inWTemice. Univariate analysis of (C) Pten and (D) Adam15 in TdTOsx+ cells from tumors grown in either WTe or KO mice, *P < 0.01,
t-test for unpaired samples. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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changed in TdTOsx+ cells, suggesting that these cells are a distinct
cell population of the tumor microenvironment with pro-
osteogenic features, but likely without the capacity of mineraliz-
ing, since Alpl, necessary for mineralization, is selectively down-
regulated. Regardless of their origin and function, these tumor
associated TdTOsx+ cells might well be the cells through which
Ncad exerts its restraining effect on tumor progression; an effect
opposite to its pro-tumorigenic action in CAF [47]. These results
indicate that Ncad exerts multiple and even opposite actions on
tumorigenesis depending on the cell context where it is expressed,
most likely through different regulatory mechanisms; while in CAF
Ncad favors tumor spreading via cell–cell adhesion and motility,
inhibition of tumor progression is via modulation of specific signal-
ing pathways in TdTOsx+ cells. These diverse, cell-specific actions
may explain the inconsistent results of clinical oncology research
on Ncad antagonism.
The proportion of Ncad+ cells within the TdTOsx+ population in
the tumor microenvironment may seem low but is consistent with
the fraction of bone marrow stromal cells that express Ncad in
healthy mice (about 10%); and Cdh2 ablation in Osx+ cells results
in low bone mass, growth delay and loss of osteogenic precursors
[4,5]. Of note, increased tumor growth in Cdh2 cKO mice does
not reflect loss of cells with an anti-tumorigenic profile, since the
number of TdTOsx+ cells is not altered by Cdh2 ablation. By contrast,
transcriptomic analysis of these tumor associated TdTOsx+ cells
show that multiple signaling pathways involved in tumor growth
are altered by loss of Ncad (Fig. 7). As occurs in cells of bone [5],
Cdh2 ablation up-regulates Lef1 and its targets in tumor associated
TdTOsx+ cells, confirming that even at extra-skeletal sites Ncad
restrains Wnt signaling. Furthermore, up-regulation of Ras and
ERK signaling components and of pro-tumorigenic targets with
consensus sequences for Sp1 and Nfat in TdTOsx+ cells from cKO
mice suggest inhibition of the Ras/MAPK cascade by Ncad. Ras
hyperactivation is associated with secretion of pro-tumorigenic
factors by CAF [53]; and Sp1 and Nfat regulate matrix proteases
and other secretory factors associated with cancer invasiveness
[54]. Inhibition of Ras/ERK by Ncad has been reported in other cell
systems [11,55], consistent with observations that Ncad restrains
tumor growth in K-ras-induced murine pancreatic tumors in a
cell-autonomous fashion [22,56]. Moreover, consistent with Ncad
inhibition of PI3K signaling [11], loss of Ncad in tumor associated
TdTOsx+ cells increases PI3K signal components and up-regulates
PI3K-dependent pro-tumorigenic targets with consensus
sequences for Nfat, MAZ, Sp1 and Lef1. Further, loss of Ncad
decreases expression of Pten, a PI3K regulator with lipid and phos-
phatase activity [57] that restrains stromal support of tumorigen-
esis via extracellular matrix remodeling and inhibition of
immune cell infiltration and angiogenesis [58,59]. Consistently,
down-regulation of PTEN, possibly via AKT hyper-activation, has
been reported in melanoma cells after treatment with the Ncad
inhibitor, ADH-1 [23]. Downstream of these pathways, we found
increased expression of Adam15, a member of a family of catalyti-
cally active disintegrin membrane metalloproteinases that func-
tion as molecular signaling switches, shed membrane bound
growth factors, and cleave type I cadherins, such as Ecad and Ncad
[60]. Notably, Adam15 activation is associated with increased
metastatic potential of cancer [61]. Thus, increased cancer growth
in Cdh2 cKO mice may be contributed to by enhanced Adam15-
dependent release of pro-tumorigenic factors in the tumor
microenvironment.
Overall, our results are consistent with a biologic model
whereby loss of Ncad hyperactivates Ras, PI3K and b-catenin sig-
naling converging on activation of Nfat, Sp1, MAZ and Lef1 and
increased production of pro-tumorigenic factors (Fig. 7). Our model
challenges the dogma that the primary role of Ncad is to promote
cancer growth via adhesive interactions between tumor and
microenvironment cells and expands its function to modulation
of specific signaling pathways active in tumorigenesis. One limita-
tion of these studies is that we used syngeneic murine models of
breast cancer that, though widely used, may not fully recapitulate
human cancer biology; therefore, it remains possible that Ncad-
driven adhesion may be more important in metastatic growth in
bone in humans. Furthermore, the transcriptomic findings must
be validated and should be considered as hypothesis building
rather then definitive mechanisms.
We have discovered a new, unexpected role for Ncad in the
interplay between cancer and its microenvironment, recasting
Ncad from a simple mediator of cell–cell adhesion to more active
player in microenviroment-tumor cell interactions. We have also
discovered a previously unrecognized branch of the mesenchy-
mal/osteogenic lineage that contributes to extra-skeletal tumor
growth and may serve yet unknown functions outside of the bone.
These observations broaden the concept of cellular heterogeneity
within the tumor microenvironment and offer a new platform for
targeting the stroma with the purpose of inhibiting tumor growth
and metastasis.
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